Released Mar 16, 2020, before the open
10-K filed Mar 16, 2020, 76 days after period end · 0001564590-20-010998
Q4 2019 · 10-K
Revenue$696.00K$696.00K −58.9% vs Q4 2018+304.7% vs Q3 2019
Net Income-$24.99M-$24.99M N/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$1.31-$1.31 N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$25,883,000N/M
Operating Cash Flowderived-$17,367,000N/M
Free Cash Flowderived-$17,496,000N/M
Margins · derived
Operating margin-3718.8%−3063.7 pt vs Q4 2018
Net margin-3589.9%−2963.5 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $696.00K | $1.69M | $993.00K | — |
| Net Income | -$24.99M | -$10.60M | -$13.86M | -$7.21M |
| EPS Diluted | -$1.31 | -$0.60 | -$1.59 | -$25.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR